This weekend finds all of us at the ADA meeting in Chicago and we have some early releases on some of the findings. The great thing about the Scientific Sessions is that researchers of new drugs, techniques and methods of diabetes care put all their work out for us to see. This conference is filled with new products as well as possible candidates for future care.
We expect to hear a lot about the SGLT2-I class and think that many of the presentations will be dominated by this new class of drugs. In order to get all that information to you we are going to prepare a special edition for you and send it next week.
In addition, we will see research on other new drug classes: one of those we have early for you is aldesleukin, a new immunologic treatment that targets the interleukin-2 (IL-2) pathway lowering the requirements of insulin for type 1 patients.
I would like to see some more positive results on some of the newer medications that have not been widely used, including Symlin (pramlintide) and Cycloset (bromocriptine immediate release) as these are medications that we can add to the arsenal today.
Dave Joffe, Editor-in-chief